Prerna Mewawalla, MD

She/Her

Associate Professor

Department: Medicine

Specialties: Hematology / Oncology

Research &
Academics
Background
Media/Publications/
Presentations
Patient
Care

Education

Medical School – Seth G.S. Medical College, Mumbai, India

Awards & Honors

Castle Connolly Top Doctor
Castle Connelly 2026 Exceptional Woman in Medicine
Induction into the Alpha Omega Alpha Honor Medical Society
U.S. Myeloma Innovations Research Collaborative Eagle Award for advancing research in plasma cell disorders
Pennsylvania Medical Society Healthcare Hero Award
2026 Faculty Professional Development, Sponsorship and Allyship Award
Doctors’ Day Certificate of Recognition, Pennsylvania Medical Society

Memberships / Professional Affiliations

International Myeloma Society
American Society of Hematology
American Society for Transplantation and Cellular Therapy
American Society of Clinical Oncology
Alpha Omega Alpha Honor Medical Society
Pennsylvania Society of Oncology and Hematology
Pennsylvania Medical Society
Allegheny County Medical Society

Prerna Mewawalla, MD, is a nationally recognized, board-certified hematologist-oncologist specializing in multiple myeloma, amyloidosis and other plasma cell disorders. At Allegheny Health Network (AHN), she serves as director of the Stem Cell Transplant and Cellular Therapy program and apheresis medical director.

Dr. Mewawalla provides comprehensive, individualized care throughout the myeloma journey — from newly diagnosed and high-risk disease to relapsed or treatment-resistant myeloma. Her expertise includes autologous stem cell transplantation, CAR T-cell therapy, bispecific antibody therapy and clinical trials. As principal investigator on several national myeloma trials, she helps expand patients’ access to promising new treatments.

Dr. Mewawalla has led major advances in cancer care at AHN, including expanding bispecific antibody treatment into community settings so patients can receive complex therapies closer to home, leading the transplant program through FACT accreditation, and helping establish AHN as a recognized amyloidosis center of excellence.

Dr. Mewawalla is a nationally and internationally invited speaker and widely published clinical investigator whose work has appeared in leading peer-reviewed journals. Her honors include recognition as a Castle Connolly Top Doctor and Exceptional Woman in Medicine in 2026, induction into the Alpha Omega Alpha Honor Medical Society, the USMIRC Eagle Award for advancing research in plasma cell disorders, and the Pennsylvania Medical Society Healthcare Hero Award.

Clinical Services

Multiple myeloma, Monoclonal gammopathy (MGUS), plasmacytoma, Amyloidosis, Stem cell collection and transplant, Bone marrow transplant, CAR T-cell therapy, Bispecific antibody therapy, BCMA-targeted therapy, Apheresis

Residencies

Internal Medicine – University of Connecticut, Hartford, Connecticut (2009–2012)

Fellowships

Hematology-Oncology – Allegheny Health Network, Pittsburgh, Pennsylvania (2012–2015)

Affiliated Hospitals

Allegheny Health Network

Prerna Mewawalla, MD, is an associate professor of medicine at Drexel University College of Medicine. Her teaching focuses on multiple myeloma, amyloidosis, stem cell transplantation, CAR T-cell therapy, bispecific antibodies and cellular therapy.

Dr. Mewawalla is actively involved in teaching medical students, internal medicine residents and hematology-oncology fellows on the bone marrow transplant inpatient service and in the outpatient clinic. She provides bedside and clinic-based education in evaluating patients, developing treatment plans, managing complications, and delivering complex cellular and immune-based therapies.

Her educational work also includes continuing medical education, invited lectures and national multimedia education for physicians. She serves as course director for the Highlights of ASH CME Conference and is an invited speaker at national and international conferences on multiple myeloma, stem cell transplantation, CAR T-cell therapy, and bispecific antibodies. She regularly translates rapidly evolving evidence into practical guidance on treatment selection, therapeutic sequencing, toxicity management, outpatient treatment and expanding access to advanced therapies.

As director of the Stem Cell Transplant and Cellular Therapy program at Allegheny Health Network, Dr. Mewawalla integrates education with multidisciplinary care, clinical research, quality improvement and program development. Her commitment to faculty development, sponsorship, mentorship and allyship was recognized with Drexel University College of Medicine’s 2026 Faculty Professional Development, Sponsorship and Allyship Award.

Research Overview

Clinical and real-world research in multiple myeloma, amyloidosis, and other plasma cell disorders, with emphasis on CAR-T cell therapy, bispecific antibodies, stem cell transplantation, treatment sequencing, high-risk disease and expanding access to advanced therapies.

Research

Dr. Mewawalla’s research focuses on improving outcomes for patients with multiple myeloma and other plasma cell disorders through clinical trials, real-world evidence and innovative models of care delivery. Her principal areas of investigation include CAR T-cell therapy, bispecific antibodies, treatment sequencing, high-risk myeloma, stem cell transplantation, amyloidosis, and the safe delivery of advanced therapies in outpatient and community settings.

Dr. Mewawalla serves as principal investigator on multiple national clinical trials evaluating novel treatments across the myeloma disease continuum, including newly diagnosed, high-risk smoldering, and relapsed or treatment-resistant multiple myeloma.

Her real-world research examines the effectiveness, safety and optimal sequencing of CAR T-cell therapies and bispecific antibodies, including outcomes following prior BCMA-directed treatment. Additional areas of investigation include high-risk cytogenetics, transplant outcomes, renal impairment in myeloma, infection prevention and barriers to clinical-trial access.

Her research is complemented by programmatic work to expand bispecific antibody treatment into community settings, streamline CAR T-cell care, reduce stem cell mobilization failures, and improve stem cell collection efficiency. Her research leadership was recognized with the 2025 USMIRC Eagle Award for advancing research in plasma cell disorders.

Publications

View Dr. Mewawalla's publications in Google Scholar.

Non-interchangeability of serum free light chain assays at IMWG thresholds: Analysis of 2,117 paired samples. Clinical Lymphoma, Myeloma & Leukemia. Accepted for publication; in press, September 2026.

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future Oncology. 2026. doi:10.1080/14796694.2026.2698699.

The ClinicalTrials.gov landscape of multiple myeloma clinical trials: A 20-year analysis of geographic distribution and growth patterns—A USMIRC analysis. Current Oncology. 2026;33(7):396. doi:10.3390/curroncol33070396.

Evaluation of real-world studies on the management of relapsed multiple myeloma after BCMA-directed therapy failure from U.S. academic centers and USMIRC. Current Oncology. 2026;33(6):355. doi:10.3390/curroncol33060355.

From episodic assessment to comprehensive assessment: Integrating real-world monitoring in relapsed or refractory multiple myeloma. Expert Review of Hematology. 2026. doi:10.1080/17474086.2026.2681764.

High-risk cytogenetic multiple myeloma remains a therapeutic challenge: A 15-year real-world analysis. Current Oncology. 2026;33(5):249. doi:10.3390/curroncol33050249.

Outcomes of double-hit and single high-risk cytogenetic newly diagnosed myeloma in transplant-eligible patients. Current Oncology. 2026;33(5):246. doi:10.3390/curroncol33050246.

Expanding bispecific T-cell engager therapy for multiple myeloma to community settings: A single-institution experience. Journal of Hematology Oncology Pharmacy. 2026;16(6).

Maintenance strategies in high-risk myeloma: A multicenter comparison of bortezomib-lenalidomide versus lenalidomide alone—A USMIRC multicenter analysis. Current Oncology. 2026;33(3):164. doi:10.3390/curroncol33030164.

A real-world analysis of the safety and efficacy of teclistamab for patients with relapsed or refractory multiple myeloma and baseline renal impairment. Cancers. 2026;18(5):740. doi:10.3390/cancers18050740.

Real-world outcomes of sequential BCMA-directed therapies in relapsed or refractory multiple myeloma after belantamab exposure. Clinical Lymphoma, Myeloma & Leukemia. 2025.

A real-world experience of the efficacy and safety of belantamab mafodotin in relapsed or refractory multiple myeloma. Blood Cancer Journal. 2025;15:34.

Delayed diagnosis of POEMS syndrome: How artificial intelligence tools can enhance diagnostic accuracy. European Journal of Case Reports in Internal Medicine. 2025;12.

Amyloid light-chain amyloidosis masquerading as scleroderma: A diagnostic challenge. Journal of Hematology. 2025.

Non-secretory multiple myeloma associated with a high-risk phenotype and complex cytogenetics, including t(8;22). Journal of Hematology. 2024.

* This physician's clinical practice is independent of Drexel University.

Contact Information

Allegheny Health Network Cancer Institute
4815 Liberty Avenue, Suite MP322
Pittsburgh, PA 15224